Navigation Links
Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data from preclinical and clinical trials of BAY 86-9766 (formerly known as RDEA119) will be presented at the 22nd European Organisation for Research and Treatment of Cancer (EORTC) – National Cancer Institute (NCI) – American Association for Cancer Research (AACR) symposium on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany.  BAY 86-9766 is a mitogen-activated ERK kinase (MEK) inhibitor licensed to and being developed by Bayer HealthCare AG.

The results of a multi-center, Phase 1, monotherapy, dose-escalation study of BAY 86-9766 in advanced cancer patients will be presented by Colin Weekes, MD, PhD, Assistant Professor, Division of Medical Oncology at the University of Colorado School of Medicine. The principal investigators for this study included Dr. Weekes, Daniel D. Von Hoff, MD, Professor of Medicine at the University of Arizona School of Medicine and Executive Vice President of the Translational Genomics Research Institute (TGen), and Alex Adjei, MD, PhD, Professor and Chair, Department of Medicine at the Roswell Park Cancer Institute. In addition, data from preclinical studies of BAY 86-9766, demonstrating its potential for administration in combination with other anti-cancer agents will be presented by Bayer.

"Based on the good tolerability and impressive number of patients who achieved stable disease in this Phase 1 monotherapy trial in refractory patients with advanced solid tumors, we believe BAY 86-9766 has the potential to be a clinically important drug in the treatment of patients across multiple tumor types," said Dr. Adjei. "These monotherapy results support our ongoing Phase 1/2 study of BAY 86-9766 in combination with sorafenib at the maximum tolerated dose defined in this trial and the continued research by Bayer Heal
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences to Present at Four Upcoming Investor Conferences
2. Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
3. Ardea Biosciences to Present at Two Upcoming Investor Conferences
4. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
5. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
10. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
11. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Therapeutics, Inc. (NASDAQ: ECTE ), a ... believes that its current liquidity is insufficient to ... has suspended its product development, research, manufacturing and ... and capital resources. The actions ... position, funding alternatives, and projected product development costs ...
(Date:9/23/2014)... , Sept. 23, 2014 Ultrasound devices ... body in order to diagnose diseases and also ... surgical instruments while performing surgeries. This report studies ... parameters such as product type, technologies, applications and ... market, based on the product type has been ...
(Date:9/23/2014)... Sept. 23, 2014 Nuclear medicine market ... Radiopharmaceuticals/ Nuclear are drugs that contain ... field to diagnose and treat diseases. ... awareness for radiopharmaceuticals, and ready availability of radiopharmaceuticals ... Furthermore, increased public awareness and use of SPECT ...
Breaking Medicine Technology:Echo Therapeutics Suspends Operations To Conserve Liquidity 2Echo Therapeutics Suspends Operations To Conserve Liquidity 3Echo Therapeutics Suspends Operations To Conserve Liquidity 4Ultrasound Devices Market (By Product Type, By Technology and By Application - Obstetrics and Gynecology, Cardiovascular, Abdominal and Others) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013 - 2019 2Ultrasound Devices Market (By Product Type, By Technology and By Application - Obstetrics and Gynecology, Cardiovascular, Abdominal and Others) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2013 - 2019 3Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019) 2
...  A consortium comprised of investment funds advised by Apax ... Plan Investment Board ("CPPIB") and the Public Sector Pension ... Kinetic Concepts, Inc. (NYSE: KCI ) have ... common share in cash, or a total value of ...
... 2011 DMC Harper University Hospital is the ... Myriad™, for brain tumor removal.  This one of a kind ... that their previously inoperable or hard to reach brain tumors ... is an automated, non-heat producing surgical device that removes tumor ...
Cached Medicine Technology:Kinetic Concepts Shareholders Approve Acquisition by Apax Partners, CPPIB and PSP Investments 2Kinetic Concepts Shareholders Approve Acquisition by Apax Partners, CPPIB and PSP Investments 3Kinetic Concepts Shareholders Approve Acquisition by Apax Partners, CPPIB and PSP Investments 4DMC Harper University Hospital is the First in Michigan to Utilize New Device for Brain Tumor Removal 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 Mel Frank, ... about cultivating, growing and harvesting marijuana. He is perhaps ... the field and he’ll be leading a special elective ... am to 5:00 pm at Oaksterdam University ... law, botany and nomenclature, harvesting and manicuring, and identifying ...
(Date:9/23/2014)... Mo. Infants, vocalizations throughout the first year ... and cooing to forming syllables and first words. ... amount of vocalizations may differ between hearing and ... that infant vocalizations are primarily motivated by infants, ... with profound hearing loss who received cochlear implants ...
(Date:9/23/2014)... PA (PRWEB) September 23, 2014 "The primary ... infection control," said an inventor from Sacramento, Ca.. "Call lights ... bedding or left hanging on the IV pole out of ... have the nurse call device whenever they need it, I ... to effectively position the nurse call device within easy reach. ...
(Date:9/23/2014)... TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS ... WHAT: , The National Institutes of Health is convening ... scientific evidence on the long-term effectiveness and potential risks ... among the nation,s top experts in the field of ... well as key NIH scientists who focus on pain ...
(Date:9/23/2014)... September 23, 2014 World of Home ... philanthropic support. Most recently, the gym has been raising ... Fitness program. Throughout the year, World of Home Fitness ... charitable causes. , Over the summer, World of Home ... Through their Ageless Fitness program, participants helped feed seniors ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:World of Home Fitness Supports Meals on Wheels 2
... Feb. 25 Francesco Federico, M.D., president ... today the completion of an affiliation between ... Medical Group, Inc., and Verdugo Hills Medical ... (IPAs).(Logo: http://www.newscom.com/cgi-bin/prnh/20081112/LAW052LOGO )Verdugo Hills Medical Group ...
... deformity due to wrong size shoesLAS VEGAS, Feb. 25 ... according to a new study presented today at the 2009 ... ( http://www.aaos.org/ ) (AAOS). As a result, these children ... study, which took place in Switzerland, included nearly 250 boys ...
... sports affects healing time for ACL injuries in young ... 300,000 Anterior Cruciate Ligament (ACL) tears occur in the ... the 2009 Annual Meeting of the American Academy ... tears are being seen in younger patients as an ...
... Two compounds developed by Northwestern University chemists have ... in protecting against cerebral palsy, a condition caused ... coordination. , "The results were just stunning, absolutely ... of Chemistry in the Weinberg College of Arts ...
... , The countries of Central Africa have joined forces ... clinical trials under best practices. CANTAM (Central Africa Network on ... is the first EDCTP-funded regional Network of Excellence to prepare ... supported by a EUR 3 million grant for the duration ...
... Va., Feb. 25 The National Hospice and Palliative ... its "Reaching Out" grants. Funded by the Department of ... access to hospice and palliative care services for rural ... providers that represent a range of community-based organizations. ...
Cached Medicine News:Health News:Lakeside Community Healthcare Continues Growth With Verdugo Hills Medical Group IPA Affiliation 2Health News:If the Shoe Fits...or Does It? 2Health News:If the Shoe Fits...or Does It? 3Health News:An Athlete's First Question: 'Doc, When Can I Return?' 2Health News:An Athlete's First Question: 'Doc, When Can I Return?' 3Health News:Stunning finding: Compounds protect against cerebral palsy 2Health News:Stunning finding: Compounds protect against cerebral palsy 3Health News:Stunning finding: Compounds protect against cerebral palsy 4Health News:CANTAM first African Network of Excellence for clinical trials 2Health News:Grants to Increase Access to Hospice and Palliative Care for Rural and Homeless Veterans Awarded by National Hospice and Palliative Care Organization 2
... workmanship are the hallmark of these stereozoom ... mind. The top (incident) circular 9W fluorescent ... while remaining cool to the touch. Binocular ... 10x to 44x zoom magnification or high-power ...
... system expandability: the first inverted microscope to ... infinity space. Multi-port design enables optical input/output ... variety of illumination and detector equipment. Extendable ... an optional light source and other attachments ...
... Megapixel color imaging camera system designed ... high performance, megapixel digital cameras provides ... view them on a PC via ... This "live" previewing capability is accompanied ...
... camera with direct digital output. Three-chip color ... Olympus wide array of high-quality color video ... and flexibility you need for an efficient ... high-resolution, real-time image of your specimen that ...
Medicine Products: